FILANA THERAPEUTICS, INC. FLNA
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
1/9
Piotroski F — financial health
-14.32
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$91.0M | — | -$32.8M | $74.4M |
| 2024 | — | -$24.3M | — | -$117.0M | $145.7M |
| 2023 | — | -$97.2M | — | -$82.4M | $137.5M |
| 2022 | — | -$76.2M | — | -$80.2M | $227.5M |
| 2021 | — | -$32.4M | — | -$52.4M | $253.9M |
| 2020 | — | -$6.3M | — | — | $92.2M |
Why these scores methodology →
Piotroski F-score: 1/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -14.32 (distress)
- Working capital / assets 0.455
- Retained earnings / assets -4.191
- EBIT / assets -0.806
- Equity / liabilities 1.693
Source: SEC EDGAR filings · CIK 0001069530 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.